P. Bonomi

421 total citations
26 papers, 337 citations indexed

About

P. Bonomi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, P. Bonomi has authored 26 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in P. Bonomi's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). P. Bonomi is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). P. Bonomi collaborates with scholars based in United States, Australia and Philippines. P. Bonomi's co-authors include William H. Warren, Steven G. Economou, E. D. Staren, David L. Roseman, Victor E. Gould, Steven D. Bines, J Baker, L. Penfield Faber, O.O. Melnyk and Alan Sandler and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

P. Bonomi

25 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Bonomi United States 9 212 169 88 82 53 26 337
Kageaki Watanabe Japan 10 288 1.4× 211 1.2× 37 0.4× 52 0.6× 43 0.8× 47 406
M. Kulke United States 8 182 0.9× 64 0.4× 126 1.4× 116 1.4× 85 1.6× 13 350
Till Plönes Germany 12 180 0.8× 224 1.3× 44 0.5× 85 1.0× 16 0.3× 53 406
Akihito Nishio Japan 9 134 0.6× 83 0.5× 33 0.4× 78 1.0× 57 1.1× 18 376
Yuji Hirami Japan 10 222 1.0× 162 1.0× 21 0.2× 96 1.2× 25 0.5× 21 405
Hideki Kuwano Japan 7 137 0.6× 113 0.7× 31 0.4× 57 0.7× 33 0.6× 23 297
Tetsufumi Kojima Japan 8 109 0.5× 109 0.6× 45 0.5× 50 0.6× 51 1.0× 22 327
P Vennin France 10 168 0.8× 114 0.7× 60 0.7× 85 1.0× 21 0.4× 23 359
S. Della Torre Italy 9 338 1.6× 89 0.5× 140 1.6× 45 0.5× 80 1.5× 22 414
Maria Koumpou Greece 8 139 0.7× 126 0.7× 25 0.3× 68 0.8× 34 0.6× 12 321

Countries citing papers authored by P. Bonomi

Since Specialization
Citations

This map shows the geographic impact of P. Bonomi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Bonomi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Bonomi more than expected).

Fields of papers citing papers by P. Bonomi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Bonomi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Bonomi. The network helps show where P. Bonomi may publish in the future.

Co-authorship network of co-authors of P. Bonomi

This figure shows the co-authorship network connecting the top 25 collaborators of P. Bonomi. A scholar is included among the top collaborators of P. Bonomi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Bonomi. P. Bonomi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hogue, Carol J., Timothy M. Kuzel, Jeffrey A. Borgia, et al.. (2019). P2.04-69 Impact of Antibiotic Usage on Survival During Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S735–S735. 6 indexed citations
3.
Batus, Marta, et al.. (2018). P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 13(10). S874–S874. 3 indexed citations
4.
Coon, John S., Sanjib Basu, L. Penfield Faber, et al.. (2010). A multi-analyte serum test for the detection of non-small cell lung cancer. British Journal of Cancer. 103(8). 1221–1228. 31 indexed citations
5.
Hensing, Thomas A., Mary J. Fidler, Fuh Yong Wong, et al.. (2010). The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib.. Journal of Clinical Oncology. 28(15_suppl). 7552–7552. 1 indexed citations
6.
Patel, Jyoti D., et al.. (2007). Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. Journal of Clinical Oncology. 25(18_suppl). 7601–7601. 18 indexed citations
7.
8.
9.
Bonomi, P., Luis Paz‐Ares, Corey J. Langer, et al.. (2005). O-099 XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): The STELLAR 2 phase III study. Lung Cancer. 49. S35–S35. 8 indexed citations
10.
Villaflor, Victoria, Lela Buckingham, M. Gale, et al.. (2005). O-110 EGFR mutations and pAKT expression as potential predictors ofgefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts). Lung Cancer. 49. S39–S39. 2 indexed citations
11.
Loehrer, Patrick J., W. Wang, Seena C. Aisner, et al.. (2004). Long-term follow-up of patients with locally advanced or metastatic thymic malignancies: The Eastern Cooperative Oncology Group (ECOG) experience. Journal of Clinical Oncology. 22(14_suppl). 7050–7050. 2 indexed citations
12.
Treat, Joseph, Michael McCleod, David M. Mintzer, et al.. (2004). Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer. Journal of Clinical Oncology. 22(14_suppl). 7130–7130. 8 indexed citations
13.
Villaflor, Victoria, John S. Coon, William T. Leslie, et al.. (2004). Potential clinical prognostic factors in non-small cell lung cancer (NSCLC) patients treated with gefitinib. Journal of Clinical Oncology. 22(14_suppl). 7088–7088. 4 indexed citations
14.
Anderson, K.M., et al.. (2000). Widespread countervailing genomic responses induced by chemotherapy or radiation as a cause of therapeutic failure. Medical Hypotheses. 54(6). 1000–1002. 2 indexed citations
15.
Rowland, Kendrith M., Salitha Reddy, P. Bonomi, et al.. (1990). Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer. 66(11). 2270–2278. 26 indexed citations
16.
Bonomi, P., M. Gale, Jamie Von Roenn, et al.. (1988). Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.. PubMed. 15(2 Suppl 1). 26–33. 15 indexed citations
17.
Bonomi, P., Edgardo Yordan, & J A Blessing. (1988). Phase I Trial of Cisplatin and Razoxane (ICRF- 159) (NSC #119875) in Advanced Squamous Cell Carcinoma of the Cervix A Gynecologic Oncology Group Pilot Study. American Journal of Clinical Oncology. 11(1). 1–2. 6 indexed citations
18.
Staren, E. D., Victor E. Gould, William H. Warren, et al.. (1988). Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation.. PubMed. 104(6). 1080–9. 86 indexed citations
19.
Vogelzang, N., et al.. (1986). Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study.. PubMed. 70(2). 293–4. 5 indexed citations
20.
Bonomi, P., et al.. (1985). Metastatic breast cancer from an occult primary provisionally identified by steroid receptor content and two-dimensional protein electrophoresis: some problems associated with the use of the latter technique.. PubMed. 3(5). 265–70.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kageaki Watanabe Breakdown of academic impact, for papers by M. Kulke Breakdown of academic impact, for papers by Till Plönes Breakdown of academic impact, for papers by Akihito Nishio Breakdown of academic impact, for papers by Yuji Hirami Breakdown of academic impact, for papers by Hideki Kuwano Breakdown of academic impact, for papers by Tetsufumi Kojima Breakdown of academic impact, for papers by P Vennin Breakdown of academic impact, for papers by S. Della Torre Breakdown of academic impact, for papers by Maria Koumpou
Rankless by CCL
2026